rs61734410 — CACNA1H Pro640Leu

Missense variant in CACNA1H encoding the CaV3.2 T-type calcium channel; the Leu640 allele has population-level associations with migraine risk and alters channel pharmacodynamics, set against a backdrop of CaV3.2's established role in hippocampal memory consolidation and synaptic plasticity.

See your personal result for CACNA1H

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

CaV3.2 — The T-Type Calcium Channel That Consolidates Memory

Every time you form a new memory, a precise choreography of ion channels must activate in hippocampal neurons at the right moment. The CaV3.2 channel11 CaV3.2 channel
T-type voltage-gated calcium channel encoded by CACNA1H; opens near the resting membrane potential, earning the "T" for transient and tiny currents is one of the key players in this process. Unlike the high-voltage-activated L-type channels that require strong depolarisation, T-type channels open with small, subthreshold voltage changes — making them ideally positioned to respond to weak synaptic inputs and gate whether those inputs are converted into durable synaptic changes. rs61734410 substitutes leucine for proline at position 640 in this channel, a region critical for channel gating. The change does not dramatically alter baseline channel function but reduces how the channel responds to certain modulating inputs, including pharmacological ones.

The Mechanism

Pro640 lies within the second intracellular loop of the CaV3.2 alpha-1H subunit, a domain involved in channel inactivation kinetics. The Pro640Leu substitution22 Pro640Leu substitution
proline is a structurally rigid amino acid that creates kinks in protein loops; replacing it with leucine, a flexible aliphatic residue, alters the loop's geometry and potentially the conformational transitions that control channel gating does not produce measurable differences in baseline CaV3.2 electrophysiology under standard conditions — current amplitude, activation voltage, and steady-state inactivation are unchanged. The variant's effect becomes detectable only when the channel is challenged: ethosuximide's ability to accelerate CaV3.2 inactivation (its core anti-epileptic mechanism) is significantly blunted for the Leu640 channel compared to wild-type Pro640.

Beyond pharmacodynamics, CaV3.2's role in cognition is well established at the channel level. CaV3.2 knockout mice show shortened LTP duration — 120 minutes versus 180 minutes in wild-type controls33 shortened LTP duration — 120 minutes versus 180 minutes in wild-type controls
Chen et al. 2012, PLoS One; LTP = long-term potentiation, the cellular correlate of memory formation; shorter LTP means synaptic changes are less durable and impaired retrieval of context-associated memory without deficits in spatial learning. A separate study documented that CaV3.2-deficient mice fail novel object and spatial object recognition tasks with high statistical significance 44 Gangarossa et al. 2014, Frontiers in Behavioral Neuroscience; novel object recognition p<0.001 compared to wild-type controls.

T-type calcium channels at synapses contribute to plasticity through a distinct mechanism: they activate at subthreshold potentials, driving calcium influx that can interact cooperatively with NMDA receptor signalling to lower the threshold for LTP induction. Nicholson & Kullmann 201755 Nicholson & Kullmann 2017
Journal of Physiology; demonstrated T-type channel- dependent, NMDA receptor-independent LTP in hippocampal interneurons showed that blocking T-type channels prevents LTP even when the standard NMDA receptor-dependent pathway is intact, establishing T-type channels as an independent gateway to synaptic strengthening.

The Evidence

Direct evidence for Pro640Leu and cognitive outcomes is limited — the variant has not been individually studied in human cognitive GWAS datasets at genome-wide significance. The biological evidence rests on the channel-level studies above and a pharmacogenetics finding: in a childhood absence epilepsy cohort, the Pro640Leu genotype was associated with higher odds of failing to achieve seizure-freedom on ethosuximide 66 Glauser et al. 2017, Annals of Neurology; OR 2.63; n=81 patients; in vitro electrophysiology confirmed blunted drug effect at Leu640 channel. A separate replication study found no significant association in a smaller cohort (n=62), highlighting the moderate and still-contested nature of this pharmacogenetic claim.

At the population level, a case-control study 77 Wang et al. 2024, Molecular Genetics & Genomic Medicine; 226 migraineurs vs 452 controls; ORadj 1.56, 95% CI 1.07-2.28 for CT genotype found the heterozygous CT genotype to be associated with migraine risk, consistent with CaV3.2's role in trigeminovascular pain signalling and cortical excitability. The ClinVar classification of this variant is Benign (multiple submitters, no conflicts), reflecting that it does not cause monogenic disease — the associations are probabilistic and polygenic.

Practical Actions

For CT and TT carriers, the most evidence-based intervention addresses the channel's known modulation by divalent cations. Magnesium is a natural blocker of T-type calcium channels — it competes with calcium at the channel pore and modulates gating through surface charge screening. This is the same class of action that gives magnesium its anti-migraine benefit in clinical trials. Supplementing magnesium glycinate or threonate supports this channel-level modulation while also providing general neurological benefits through NMDA receptor regulation.

DHA (docosahexaenoic acid) incorporates into neuronal membrane phospholipids and maintains the membrane fluidity required for optimal ion channel conformational dynamics. Membranes depleted in DHA are more rigid, altering the voltage- sensing properties of embedded channels including T-type calcium channels. For TT carriers facing the greatest Leu640 channel dosage, ensuring adequate DHA intake supports the membrane environment in which CaV3.2 operates.

If you or a family member carry this variant and are being treated for childhood absence epilepsy with ethosuximide, the pharmacogenetics data provide a rationale for discussing alternative or adjunctive agents with a neurologist, as the Leu640 channel shows reduced pharmacodynamic sensitivity to ethosuximide's mechanism.

Interactions

CaV3.2 operates in concert with the broader T-type channel family: CaV3.1 (CACNA1G) and CaV3.3 (CACNA1I) are expressed in overlapping brain regions and can partially compensate for CaV3.2 deficiency in some circuits. Variants in CACNA1A (rs10405121), which encodes the P/Q-type CaV2.1 channel dominant in cerebellar and cortical neurons, represent a distinct calcium channel pathway but converge on similar migraine and neurocognitive phenotypes. The migraine risk from rs61734410 is expected to be additive with TRPM8 locus risk (rs10166942), which operates through a separate cold-pain threshold mechanism.

Drug Interactions

ethosuximide reduced_efficacy literature

Nutrient Interactions

magnesium altered_metabolism
DHA (docosahexaenoic acid) increased_need

Genotype Interpretations

What each possible genotype means for this variant.

CC Pro/Pro (Wild Type) Normal

Common genotype — standard CaV3.2 channel function and population-average migraine susceptibility at this locus

You carry two copies of the C allele (proline at position 640), the most common genotype globally at rs61734410, found in approximately 48% of people. This is the population-typical CaV3.2 channel configuration. The Pro640 residue produces normal channel inactivation kinetics and full pharmacodynamic sensitivity to drugs that target this channel, including ethosuximide. Your migraine susceptibility and cognitive function at this specific locus are at the population average.

CT Pro/Leu (Heterozygous) Intermediate

One copy of the Leu640 allele — modestly elevated migraine susceptibility and partial reduction in CaV3.2 pharmacodynamic sensitivity

The Pro640Leu substitution sits in the second intracellular loop of the CaV3.2 alpha subunit, a region involved in the conformational changes that control channel inactivation. Electrophysiology studies (Glauser et al. 2017) showed that the Leu640 channel is functionally indistinguishable from wild-type in the absence of drug challenge — activation voltage, current amplitude, and steady-state inactivation are all normal. The difference surfaces when ethosuximide is applied: the drug's ability to accelerate CaV3.2 inactivation is significantly blunted for Leu640 channels.

CaV3.2 is expressed in hippocampal CA1 neurons, dentate gyrus, and thalamic relay nuclei. Animal models consistently link CaV3.2 function to LTP duration and hippocampus-dependent context memory retrieval. The Leu640 substitution does not abolish channel function but may alter its modulation in contexts (pharmacological or physiological) that rely on the Pro640 loop geometry.

TT Leu/Leu (Homozygous) High Risk

Two copies of the Leu640 allele — highest CaV3.2 variant load at this locus, with reduced channel pharmacosensitivity and elevated migraine susceptibility

CaV3.2 knockout mice — a model analogous to complete loss of channel function — show markedly impaired hippocampus-dependent context memory retrieval, novel object and spatial object recognition (p<0.001), and shortened LTP duration from 180 to 120 minutes. While the Leu640 variant does not abolish channel function (baseline electrophysiology is normal), having two copies of the variant may cumulatively alter channel modulation under physiological conditions that rely on precise inactivation-loop dynamics.

In the Glauser 2017 pharmacogenetics cohort, the P640L allele appeared more frequently among ethosuximide non-responders (OR 2.63 across CT and TT genotypes combined). The in vitro data confirmed that ethosuximide's hallmark effect — accelerating CaV3.2 decay — is significantly blunted for the Leu640 form. As a TT homozygote, all your CaV3.2 channels carry the variant form that shows this reduced pharmacodynamic response.

Magnesium modulates T-type calcium channels through two complementary mechanisms: direct pore block (competing with calcium entry) and surface charge screening (shifting the voltage-dependence of activation). Both mechanisms operate independently of the Pro640Leu substitution, making magnesium a particularly relevant intervention for TT carriers who lack reliable channel pharmacodynamic response to ethosuximide.